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Introduction
============

Idiopathic intracranial hypertension, also known as benign intracranial hypertension or pseudotumour cerebri, is a condition of unknown cause characterised by raised intracranial pressure and papilloedema.[@ref1] It typically affects young obese women, causing disabling daily headaches and loss of vision, which is severe and permanent in up to a quarter.[@ref2] The incidence of idiopathic intracranial hypertension among obese women is 20 per 100 000, and the prevalence is predicted to rise in conjunction with the global epidemic of obesity.[@ref3]

There is insufficient evidence to guide therapeutic strategies, as highlighted in the 2005 Cochrane review.[@ref4] The condition has a striking association with obesity (greater than 93%),[@ref5] and consequently weight loss is often suggested as a treatment. Nevertheless, there has been only one previous prospective weight modifying study, carried out 35 years ago, which observed subjective improvement in the papilloedema in nine patients on a low calorie rice diet[@ref6]; these findings were supported by retrospective review of case notes.[@ref7] [@ref8] [@ref9] These studies relied on subjective observation of papilloedema and included people with newly diagnosed idiopathic intracranial hypertension, many of whom improve irrespective of any treatment given. Furthermore, they did not monitor concomitant changes in intracranial pressure with either weight loss or resolution of papilloedema.

We carried out a detailed examination of the interplay between weight loss in patients with idiopathic intracranial hypertension with objective measures of papilloedema and visual function, headache scores and, crucially, changes in intracranial pressure.

Methods
=======

Participants
------------

Women with idiopathic intracranial hypertension were identified and recruited from the Birmingham and Midland Eye Centre, University Hospitals Birmingham NHS Foundation Trust, and University Hospitals of Leicester NHS Trust. Idiopathic intracranial hypertension was diagnosed according to the modified Dandy criteria,[@ref10] with all patients having normal findings on magnetic resonance imaging and venography, papilloedema, intracranial pressure \>25 cm H~2~O, and duration of disease over three months at enrolment. Women were excluded if they had undergone previous cerebrospinal fluid diversion or optic nerve sheath fenestration, were pregnant or planning to conceive, had relevant comorbidity, or were aged less than 16. All women who met the inclusion criteria were invited to take part in the study.

Study design
------------

Twenty five women were prospectively recruited into a three stage study. Stage 1 was a three month period of no new intervention (control phase); stage 2 comprised a three month intensive diet; and stage 3 was a three month follow-up after completion of the diet (fig 1)[](#fig1){ref-type="fig"}. Weight loss was achieved with a previously validated,[@ref11] nutritionally complete, low energy, total meal replacement liquid diet (Lipotrim, Howard Foundation, Cambridge), which provided women with a total of 1777 kJ/day (425 kcal/day). Patients were advised to consume no additional food, and drink at least 2 litres of fluid a day. During stage 2 all participants underwent weekly review conducted at the Wellcome Trust Clinical Research Facility at the University Hospitals Birmingham NHS Foundation Trust. Compliance with the diet was monitored through evaluation of weight lost and presence of urinary ketones (a feature of abstaining from food intake). Participants were also regularly encouraged, through the provision of weekly nutritional counselling.

![**Fig 1** Summary of study design. Vision assessments include measurement of papilloedema by ultrasonographic evaluation of optic disc elevation and nerve sheath diameter as well as optical coherence tomography measurement of retinal nerve fibre layer, LogMAR visual acuity, Humphrey visual field 24-2 mean deviation, Pelli-Robson contrast sensitivity, and Farnsworth-Munsell 100 hue colour assessment. Symptoms evaluated include headache, tinnitus, visual loss, obscurations and diplopia. Lumbar puncture was carried out only at baseline, three and six months](sina726950.f1_default){#fig1}

Participants were evaluated at baseline and at the end of each stage. Anthropometric data were collected and body mass index (BMI) calculated. The presence of symptoms (tinnitus, visual loss, diplopia, visual obscurations, and headache) together with medication use was recorded. Assessment of visual function under standardised luminescence was carried out with a LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation, a Pelli-Robson chart to evaluate contrast sensitivity, and a Farnsworth-Munsell 100 hue test to appraise colour vision. (See appendix A on bmj.com for details.)

Papilloedema was evaluated with masked ultrasonography of the optic disc elevation and nerve sheath diameter (maximal retrobulbar pial diameter) by using a high resolution brightness scan (B-scan) with emission frequency 20 MHz and 10 MHz, respectively (Quantel Medical, Clermont-Ferrand, France). Additionally, peripapillary retinal nerve fibre layer thickness was measured by optical coherence tomography (Stratus OCT V4.0.1, Carl Zeiss, Meditec, Welwyn Garden City). At each visit a neuro-ophthalmologist carried out masked papilloedema grading of fundus photographs (Frisen rating scale 0 to 5, the latter being most severe (see appendix B on bmj.com).[@ref12]

Headache phenotype (according to criteria from the International Headache Society)[@ref13] was assessed at baseline. Women completed a daily headache diary in the week before each visit, in which they evaluated severity with a visual analogue pain scale (0-10), headache frequency (days/week), and use of analgesia (days/week). The women also completed a headache questionnaire (headache impact test-6 score range 36-78).[@ref14]

Intracranial pressure was measured by lumbar puncture at baseline and at the end of stages 1 and 2 after all listed outcome measures had been assessed. Measurements were taken with the patient breathing steadily in the left lateral position, legs extended greater than 90° at the hip, with adequate time taken to ensure a stable reading.

Statistical analysis
--------------------

Statistical analysis was performed with SPSS for Windows version 15.0 (SPSS, Chicago, IL) and Prism for Windows version 5.0 (GraphPad Software Inc, San Diego, CA) software packages. Data were reported with means and standard deviations. Serial measurements were analysed with repeated measures: analysis of variance (for parametric or log transformed data) or Friedman's test, with post hoc evaluation achieved with a Wilcoxon signed rank test (for non-parametric data). We analysed dichotomous variables with a Cochran's Q test, and evaluated changes in categorical data with the sign test. Associations between clinical parameters and objective outcome measures were analysed with Pearson's correlation for parametric data and Spearman's rank correlation for non-parametric data. Data were analysed only if present at all time points for each individual. The level at which the results were judged significant was P\<0.05 (or P\<0.017 for Wilcoxon signed rank test and Sign test as three pairwise comparisons were being made per variable). As data for the right and left eye correlated significantly and yielded analogous results, we have presented only right eye data.

Results
=======

Of 37 women identified, 25 agreed to take part and 12 declined because of concerns about repeated lumbar puncture. All 37 women had homogeneous characteristics. Among those who agreed to take part, one woman was subsequently excluded as she was found to have a secondary cause of raised intracranial pressure, two did not complete stage 2 of the study as they could not tolerate the diet, and two were lost to follow-up at the final study visit. Women who withdrew from the study had similar clinical and anthropometric characteristics to those remaining in the study. Table 1 shows participants' demographics[](#tbl1){ref-type="table"}. During the study 11 (44%) patients received an unchanging dose of acetazolamide. No other drugs for idiopathic intracranial hypertension were used. There were minimal side effects associated with the low energy diet: constipation (three patients), light headed feelings (ameliorated by increased fluid intake) (two), and halitosis (one). None of the women underwent diversion of cerebrospinal fluid or fenestration of the optic nerve sheath during the study.

###### 

 Baseline demographics in 25 women with idiopathic intracranial hypertension before starting low energy diet

                                           Data
  ---------------------------------------- -------------
  Mean (SD) age (years)                    34.4 (9.2)
  Ethnicity:                               
   White                                   20
   African-Caribbean                       3
   South West Asian (Indo-Pakistani)       2
  Mean (SD) duration of disease (months)   39.0 (49.2)
  Taking acetazolamide                     11

Twenty women completed the entire study and formed the cohort for the analyses. At baseline, mean values were 101.5 (SD 16.0) kg for weight, 38.2 (5.0) for BMI, and 39.8 (5.1) cm H~2~O for intracranial pressure (table 2)[](#tbl2){ref-type="table"}. Universal papilloedema was confirmed with ultrasonography and optical coherence tomography, the most common grade being Frisen grade 2 (16 of 20 cases), with the remainder grade 1 (4 of 20 cases). There was minimal evidence of visual loss, with mean LogMAR acuity of −0.02 (SD 0.10) and mean Humphrey visual field mean deviation of −3.8 (SD 4.1) (that is, a low deviation from the variance observed in the general population). Eight women described symptoms of visual loss (such as blurred or distorted vision and blind spots). At the start of the diet three women reported visual obscurations, and 10 reported tinnitus. Seven reported diplopia at the beginning of stage 2. Headache was almost universally reported (19 of 20 patients) and represented a major source of morbidity (mean headache impact test-6 score 57.5, SD 9.0). Baseline headache phenotyping indicated that 12 out of 20 women had migrainous headache (International Headache Society (IHS) classification 1.1, 1.2, and 1.5.1) in addition to headache attributed to idiopathic intracranial hypertension (IHS 7.1.1) and seven described medication overuse.[@ref13]

###### 

 Study characteristics and symptom chronology at each assessment. Figures are means (SD) unless stated otherwise

  Characteristic                                                               Baseline       Start diet     End diet       Final          P value\*
  ---------------------------------------------------------------------------- -------------- -------------- -------------- -------------- -----------
  Weight (kg)                                                                  101.5 (16.0)   102.5 (16.8)   86.8 (15.6)    87.0 (12.9)    \<0.001
  BMI                                                                          38.2 (5.0)     38.6 (5.3)     32.6 (4.7)     32.8 (4.4)     \<0.001
  Intracranial pressure (cm H~2~O)                                             39.8 (5.1)     38.0 (5.0)     30.0 (4.9)     ---            \<0.001
  Vision:                                                                                                                                  
   Optic disc elevation (ultrasonography) (mm)                                 1.02 (0.30)    0.97 (0.31)    0.82 (0.28)    0.75 (0.26)    0.002
   Optic nerve sheath diameter (ultrasonography) (mm)                          4.5 (1.0)      4.7 (1.0)      4.0 (1.2)      3.6 (1.2)†     0.004
   Retinal nerve fibre layer distension (optical coherence tomography) (µm)‡   144.1 (45.5)   135.0 (48.0)   109.3 (27.9)   108.2 (28.6)   0.001
   LogMAR visual acuity§                                                       −0.02 (0.10)   0.01 (0.11)    −0.06 (0.09)   −0.07 (0.08)   \<0.001†
   Pelli-Robson contrast sensitivity§                                          1.58 (0.17)    1.61 (0.11)    1.67 (0.05)    1.68 (0.10)    0.003
   Humphrey visual field 24-2 mean deviation§                                  −3.8 (4.1)     −3.4 (3.7)     −2.7 (3.0)     −1.5 (1.8)†    0.162
   Farnsworth-Munsell 100 hue colour assessment‡                               110.7 (86.5)   89.3 (84.6)¶   65.7 (54.9)¶   61.3 (62.0)¶   0.027
  Headache:                                                                                                                                
   Impact test (HIT-6)§                                                        57.5 (9.0)     54.5 (1.0)     46.9 (10.1)    48.4 (9.6)     0.004
   Severity (VAS score 0-10)§                                                  3.8 (2.4)      4.2 (2.8)      1.9 (2.8)      2.6 (2.7)      0.015
   Frequency (days/week)§                                                      3.8 (2.9)      4.4 (2.9)      2.1 (2.8)      2.6 (3.1)      0.011
   Analgesic use (days/week)§                                                  2.2 (2.7)      2.2 (2.5)      0.2 (0.4)      1.0 (2.1)      0.007
  No (%) with symptoms:                                                                                                                    
   Headache\*\*                                                                19 (95)        19 (95)        12 (60)        10 (50)        \<0.001
   Tinnitus\*\*                                                                10 (50)        10 (50)        4 (20)         4 (20)         0.004
   Visual loss\*\*                                                             8 (40)         7 (35)         3 (15)         1 (5)          0.063
   Obscurations\*\*                                                            3 (15)         4 (20)         0 (0)          0 (0)          0.025
   Diplopia\*\*                                                                0 (0)          7 (35)         0 (0)          0 (0)          0.008

BMI=body mass index; LogMAR=log of minimal angle of resolution; HIT-6=headache impact test-6; VAS=visual analogue score.

\*Summary statistics represent values for women who completed study (n=20). P values indicate changes after weight reduction (start diet *v* end diet; stage 2). No significant changes were noted from baseline to start diet (stage 1) or from end diet to final visit (stage 3) unless indicated.

†Significant improvement noted but not found in left eye.

‡Data logged before analysis.

§Friedman's test used for analysis. If result was significant, Wilcoxon sign rank test subsequently carried out, results of latter quoted in table.

¶Significant change noted after each stage, therefore weight loss stage did not significantly improve variable. All data analysed (at four time points, except intracranial pressure, which was analysed at three time points) with repeated measures analysis of variance unless stated otherwise.

\*\*Cochran's Q test showed significant improvement in all variables; sign test subsequently used to evaluate differences at each study stage.

As expected, none of the measured variables altered significantly during stage 1 (no intervention). After the low energy diet (stage 2), mean weight fell by 15.7 (SD 8.0) kg (P\<0.001; −15.3% (SD 7.0%) of weight) and mean intracranial pressure by −8.0 (SD 4.2) cm H~2~O (P\<0.001) (fig 2).\[f2\] Although all women lost weight and reduced their intracranial pressure, the change in pressure during the low energy diet did not correlate with change in weight (*r*=0.280, P=0.209) nor with changes in any of the other outcome measures.

![**Fig 2** Assessment of change in weight and intracranial pressure](sina726950.f2_default){#fig2}

Figure 3[](#fig3){ref-type="fig"} shows that all three measurements used to objectively evaluate different aspects of papilloedema significantly improved after weight loss (stage 2): elevation of the optic disc (P=0.002), diameter of the optic nerve sheath (P=0.004), and thickness of peripapillary retinal nerve fibre layer (P=0.001). There was, however, no significant improvement in the less discriminating Frisen grade during stage 1 or 2. The actual LogMAR visual acuity score improved significantly (P\<0.001), but this equated to an improvement of only one line (0.1) in five women and was not considered clinically relevant. The Pelli-Robson contrast sensitivity score improved significantly after weight loss (stage 1: four patients improved, two deteriorated; stage 2: eight patients improved, one deteriorated; P=0.003). During the course of the study, we also noted small improvements in Humphrey visual field mean deviation (0.4 (SD 1.6) for stage 1 (P=0.110) and 0.7 (SD 2.4) for stage 2 (P=0.162)) and Farnsworth-Munsell colour assessment (−21.4 (SD 49.7) for stage 1 (P=0.012) and −23.6 (SD 45.3) for stage 2 (P=0.027)). This reflects a learning effect in participants and not a response to weight reduction.[@ref15]

![**Fig 3** Quantification of papilloedema. Optic disc elevation: in ultrasound image, callipers measure from maximum disc height to lamina cribrosa; scatter plot shows means. Optic nerve diameter: in ultrasound image, callipers mark maximum pial diameter, short arrow indicates cross section through optic nerve, long arrow marks distended cerebrospinal fluid; scatter plot shows means. Retinal nerve fibre layer: in optical coherence tomogram image, arrow marks peripapillary distension; scatter plot shows means. P values are for changes from previous time point](sina726950.f3_default){#fig3}

Headache (measured by headache impact test-6) significantly improved after weight loss to a score of 46.9 (SD 10.1) (P=0.004) (fig 4)[](#fig4){ref-type="fig"}. Figure 4 also shows significant improvements in headache severity (visual analogue pain score from 4.2 (SD 2.8) to 1.9 (SD 2.8), P=0.015), headache frequency (from 4.4 (SD 2.9) to 2.1 (SD 2.8) days a week, P=0.011), and weekly use of analgesics (from 2.2 (SD 2.5) to 0.2 (SD 0.4) days a week, P=0.007) (table 2)[](#tbl2){ref-type="table"}. Patients' symptoms (headache, tinnitus, obscurations, and diplopia) showed significant improvement after the low energy diet (stage 2) (P\<0.001, P=0.004, P=0.025, and P=0.008, respectively) (table 2).[](#tbl2){ref-type="table"}

![**Fig 4** Headache impact test-6 scores and headache diary assessment, shown as mean changes (95% confidence intervals) from previous time point in headache severity (visual analogue pain score: 0=no pain, 10=maximum pain), headache frequency, and use of analgesics](sina726950.f4_default){#fig4}

At the final visit three months after the end of the diet (end of stage 3, table 2), all outcome measures including weight (0.2 (SD 2.5) kg, P=0.894) were unchanged, with the exception of headache symptoms (P=0.002), papilloedema (nerve sheath diameter −0.4 (SD 0.8) mm, P=0.035, and disc elevation −0.07 (SD 0.15) mm, P=0.059), and mean deviation of the Humphrey visual field (1.2 (SD 2.0), P=0.009), which continued to improve.

Discussion
==========

In this small prospective study, women with idiopathic intracranial hypertension who followed a low energy (calorie) diet for three months had significantly reduced intracranial pressure compared with pressure measured in the three months before the diet (headaches and papilloedema also significantly improved). In the three months after the diet ended, weight loss was maintained and improvements in headache, papilloedema, and vision persisted. These findings suggest that weight reducing diets can help in the management of idiopathic intracranial hypertension.

In four of the 20 women, intracranial pressure fell to a "normal" level (below 25 cm H~2~O). In the 16 women whose intracranial pressure remained above 25 cm H~2~O, 13 became asymptomatic for tinnitus, visual loss, diplopia, and visual obscurations after weight loss, compared with four at baseline. These data highlight that it might not be necessary for people with idiopathic intracranial hypertension to reduce their intracranial pressure to below defined normal levels to achieve measurable symptomatic relief. This might, however, be an overly simplistic concept as obesity is known to marginally increase intracranial pressure,[@ref16] and the equilibrium of cerebrospinal fluid dynamics in resolving idiopathic intracranial hypertension might be re-set such that apparent normality occurs at higher pressures. There was also an absence of a direct relation between weight loss and change in intracranial pressure, potentially suggesting a more complex relation, which could be influenced by a weight threshold for raised intracranial pressure in individual patients.

Measured variables
------------------

Papilloedema, objectively measured with optical coherence tomography, ultrasonography of optic disc elevation, and optic nerve sheath diameter, as well as symptoms (headache, tinnitus, obscurations, and diplopia), all significantly improved after the low energy diet. Papilloedema continued to resolve during stage 3, despite weight remaining stable. This probably reflects a relatively slow resolution of optic disc axonal distension and oedema after reduction in intracranial pressure. Delayed resolution of papilloedema is also noted after normalisation of intracranial pressure after cerebrospinal fluid shunting for idiopathic intracranial hypertension (that is, the papilloedema resolves over a period ranging from three weeks to seven months after surgery).[@ref17] The headache impact score, which was substantial at baseline (57.5 (SD 9.0)), significantly improved after the low energy diet (P=0.004) to a level that had no or little impact on daily life (46.9 (SD 10.1)) (disability quantification from [www.headachetest.com/HIT6translations.html](www.headachetest.com/HIT6translations.html)).[@ref18] A subgroup of women (eight out of 20) continued to report disabling headaches after the diet, characterised by a score of \>50 on the headache impact test-6, despite a reduction in weight and intracranial pressure equivalent to that of the whole study cohort. Alternative headache phenotypes such as migraine could account for the headache morbidity in these women.

The extent of weight reduction (loss of over 15% of body weight) is important as numerous other weight loss strategies had previously failed in these women. The low energy diet entailed consumption of three low energy nutrition drinks a day, which varied in flavour. Compliance and consequent universal effectiveness of the diet reflected patients' satisfaction with the regime. This was attributed to the individual weekly review sessions; weekly evidence of successful weight loss, a dependable consequence of consuming only 1777 kJ/day (425 kcal/day), and a powerful motivating factor; and ketosis, which enhanced hypothalamic satiety, reducing hunger and food cravings once the diet was established. The struggle for patients to achieve and maintain weight reduction however, is, universally recognised. Weight loss through low energy diets, gradual energy restriction, or exclusion of macronutrients (fat, carbohydrates, or protein) could be a little as 2-4 kg at two years.[@ref19] Other non-dietary strategies to encourage weight loss include pharmacological and surgical interventions. Pharmacological treatment for obesity, despite tolerability, is unlikely to achieve sufficient weight loss to greatly modify idiopathic intracranial hypertension. After 12 months' treatment, mean weight loss is 2.89 kg with orlistat[@ref20] and 4.45 kg with sibutramine.[@ref21] Additionally, after concerns about cardiovascular risk, the European Medicines Agency recently withdrew the prescribing licence for sibutramine and the National Institute for Health and Clinical Excellence (NICE) withdrew recommendations for its use.[@ref22] Topiramate might be a more useful weight modifying drug (reduces weight by 9.75 kg at 12 months in patients with idiopathic intracranial hypertension),[@ref23] with additional potential to reduce cerebrospinal fluid secretion via carbonic anhydrase inhibition[@ref24] and efficacy in treating coexisting migraine. Bariatric surgery could be effective, and one study reported a resolution of papilloedema in a series of eight patients.[@ref25] Although the advantage of this approach has previously been limited by unacceptable morbidity, recent studies indicate improved safety and efficacy of laparoscopic bariatric surgery and provide rationale for the re-evaluation of this technique in people with idiopathic intracranial hypertension.[@ref26]

Strengths and weaknesses
------------------------

This was a small study with only 25 patients, which inevitably leads to limitations in interpretation. Because of the intensity of the low energy diet intervention and the detailed clinical protocol, however, performing a study in large numbers of patients before this prospective cohort study might not have been ethically viable.

Evaluation of papilloedema in previous therapeutic studies of idiopathic intracranial hypertension has relied on subjective observation; our use of previously described objective imaging measures[@ref27] [@ref28] marks an important advance in gauging optic disc swelling that will enhance research and contribute to future clinical trial design. We acknowledge that lumbar puncture, which records only a snapshot assessment of intracranial pressure, is not as accurate as 24 hour continuous monitoring, which reflects diurnal fluctuations in intracranial pressure. The minimal changes in intracranial pressure reported over stage 1 (−1.8 (SD 5.5) cm H~2~O without intervention), however, indicate that the variability in intracranial pressure did not significantly influence our data. We recognise that the non-randomised controlled nature of our study design needs to be taken into account when evaluating these data. Patients' acceptability and ethical considerations prevented recruitment to a control cohort (which would require serial lumbar puncture---a procedure with associated morbidity). Although our study, like other observational case series, might have been prone to unrecognised bias, confounding factors, or, potentially, overestimation of therapeutic magnitude, a rigorous study design like ours can minimise these potential limitations.[@ref29] A major strength of this study is that all patients had chronic stable idiopathic intracranial hypertension (mean disease duration 39.0 (SD 49.2) months). This reduced the risk of bias from the possibility of rapid spontaneous resolution, which is a recognised phenomenon in some patients with acute idiopathic intracranial hypertension. A consequence of selecting a chronic cohort was that visual impairment was minimal and papilloedema was mild (Frisen grades all ≤2) in most women at enrolment. We did not include patients with a history of rapidly declining vision requiring cerebrospinal fluid diversion surgery or other aggressive treatment. Visual function (LogMAR score and Humphrey visual field) was preserved at baseline in our participants, and a clinically important improvement was not noted nor expected. Despite studying a cohort with chronic idiopathic intracranial hypertension, we observed clinically and statistically significant improvements in symptoms and papilloedema.

Comparison with other studies
-----------------------------

The only previous prospective study of therapeutic weight loss in idiopathic intracranial hypertension merely assessed subjective changes in papilloedema and included only nine patients.[@ref6] We not only used objective measures to quantify changes in papilloedema but additionally observed intracranial pressure in patients after a low energy diet.

Implications and future research
--------------------------------

After a low energy diet, women with idiopathic intracranial hypertension had significantly reduced intracranial pressure, headaches, and papilloedema. Our findings suggest that advising and encouraging such patients to embark on and maintain a weight reducing diet could be of therapeutic benefit. Weight loss clinics could have a role in the management of idiopathic intracranial hypertension, though the long term effectiveness and heath economics of this approach will require critical evaluation in a further study comparing weight reduction using NHS dieticians with specially designated weight reduction clinics for patients with idiopathic intracranial hypertension.

### What is already known on this topic

1.  Over 93% of patients with idiopathic intracranial hypertension are obese

2.  Weight loss is a commonly advocated treatment for idiopathic intracranial hypertension, but there is little prospective evidence for efficacy

### What this study adds

1.  Weight reduction in women with idiopathic intracranial hypertension was associated with reduced intracranial pressure (measured by lumbar puncture), papilloedema, and symptoms including headache

2.  Encouraging patients with idiopathic intracranial hypertension to embark on and maintain a weight reducing diet might be helpful

3.  The use of objective imaging measures to quantify papilloedema in idiopathic intracranial hypertension mark an important advance that will enhance clinical care and contribute to design of future clinical trials
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